Ultimaster™ Sirolimus Eluting Coronary Stent System | 合法醫療器材資訊網

Drugdoseanddeliveryfacilitateearlyvesselrecovery·​Terumo'ssecond-​generationbioresorbablepolymercoating(PDLLA/PCL)eliminatesthelong-​term ...

1 Data on file at Terumo Corporation (Doc nr. BioRes02-T). 2 Ultimaster IFU. 1 month DAPT CE Mark approved for patients in need. Patients should be maintained on clinically adequate post-procedural antiplatelet therapy according to the current guidelines. In case of need, dual antiplatelet therapy can be discontinued earlier, but not before one month. 3 ​Comparing to DES with uniform coating. Saito N. et al. Drug diffusion and biological responses of arteries using a drug-eluting stent with nonuniform coating. Medical Devices: Evidence and Research 2016:9. 4 Virmani R. CvPath Rabbit Iliac artery. Barbato E. Presented at EuroPCR 2013. 5 Data on file at Terumo Corporation (Doc nr. Grad01-T). 6 Orvin K et al. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial. Catheter Cardiovasc Inter v. 2...